Prospective study of human parvovirus (B19) infection in pregnancy

Hall, SM; Bj, Cohen; Mortimer, P P; Caul, E.O.; Cradock-Watson, J. E.; Ml, Anderson; Pattison, J R; Shirley, JA; Tea., Peto

doi:10.1016/0020-7292(91)90244-y

Cited by 54 publications

(33 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seroprevalence studies have shown that approximately 30-40% of women are not immune, therefore do not possess B19 antibodies, and are consequently at risk of B19 infection. A vertical transmission rate of 33% has been reported by the United Kingdom Public Health Laboratory Service (PHLS, 1990) and similar rates have been reported in other studies (Brown et al, 1984;Hall et al, 1990), although a recent report has disclosed a transmission rate of 51% (Yaegashi, 2000). On the basis of 4 million births occurring in Europe per annum (Eurostat, 1998), an average B19 seronegativity of 30% among pregnant women and a seroconversion rate for women of child-bearing age of 0.1-1%, it can be estimated, that up to 14,000 women will seroconvert during pregnancy.…”

Section: B19 Infection and Pregnancysupporting

confidence: 59%

“…Significantly, B19 can also be transmitted transplacentally from an infected mother to the foetus, on occasion leading to non-immune foetal hydrops (NIHF), spontaneous abortion or intrauterine foetal death (IUFD) Miller et al, 1998;Skjoldebrand-Sparre et al, 2000). A range of vertical transmission rates for maternal-foetal infection of 7-33% have been reported (Enders and Biber, 1990;Hall et al, 1990;Yaegashi, 2000). The P blood group antigen, which acts as a receptor for B19, has been detected on cells of the villous trophoblast of placental tissues in varying amounts during the course of pregnancy.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Human Parvovirus B19: Molecular Virology, Clinical Features, Prevalence, Diagnosis and Control

Corcoran¹,

Doyle²

2006

Congenital and Other Related Infectious Diseases of the Newborn

View full text Add to dashboard Cite

Parvovirus B19-introductionParvovirus B19 (B19) is an erythrovirus and recent studies have classified B19 as a genotype 1 erythrovirus with genotypes 2 (erythrovirus K71 or A6) and 3 (erythrovirus V9) also present in the human population. B19 is a significant human pathogen which can cause foetal hydrops and foetal death if maternal infection, followed by transplacental QA :1 foetal infection, occurs during pregnancy. The virus is also transmitted by inter-personal contact and potentially via blood product administration. Symptoms of B19 infection include malaise, rash and anthralgia. Significantly, maternal B19 infection during pregnancy can be asymptomatic and so careful monitoring of at-risk pregnancies is recommended. Both antibody-and cell-mediated immunity play an important role in the anti-viral response and effective diagnostic test systems, for both B19 antibody and DNA detection, are now available. B19-induced foetal hydrops can be effectively treated by intrauterine blood transfusion; however, no vaccine is available to prevent infection at present.

show abstract

Section: B19 Infection and Pregnancysupporting

confidence: 59%

mentioning

confidence: 99%

Human Parvovirus B19: Molecular Virology, Clinical Features, Prevalence, Diagnosis and Control

Corcoran¹,

Doyle²

2006

Congenital and Other Related Infectious Diseases of the Newborn

View full text Add to dashboard Cite

show abstract

“…While the majority of pregnant women presenting with B19V infection go on to deliver healthy full-term infants, approximately 5 to 9% of the pregnancies may end in fetal death (9,16). Although poor outcome is infrequent, pregnant women lacking B19V-specific antibodies or demonstrating measurable levels of B19V-specific IgM will likely be monitored weekly by ultrasound for 8 to 10 weeks.…”

Section: Discussionmentioning

confidence: 99%

“…During pregnancy, congenital infection with human parvovirus B19 (B19V) can be associated with poor outcome, including miscarriage, fetal anemia, and nonimmune hydrops (1,6,8,9,13,18). Diagnosis of acute B19V infection in a pregnant woman, as defined by detection of measurable levels of B19V-specific immunoglobulin M (IgM) or a Ն4-fold rise in levels of B19V-specific IgG, can precipitate weekly ultrasonographic monitoring for a minimum of 8 to 10 weeks (3).…”

mentioning

confidence: 99%

Comparison of Three Commercially Available Serologic Assays Used To Detect Human Parvovirus B19-Specific Immunoglobulin M (IgM) and IgG Antibodies in Sera of Pregnant Women

Butchko

Jordan

2004

J Clin Microbiol

View full text Add to dashboard Cite

show abstract

“…B19 also causes erythema infectiosum and a transient arthritis (Reid et al, 1985). When it occurs during the early part of pregnancy it leads to an increased risk of second-trimester abortion (Hall et al, 1990) and is also a cause of hydrops fetalis (Brown et al, 1984;Porter et al, 1988).…”

Section: Introductionmentioning

confidence: 99%

The production of human parvovirus capsid proteins in Escherichia coli and their potential as diagnostic antigens

Rayment

Crosdale²,

Morris³

et al. 1990

Journal of General Virology

View full text Add to dashboard Cite

We have expressed a number of polypeptides derived from the capsid proteins of the human parvovirus B 19 in Escherichia coli. These include native VP1 (8410 and VP2 (58K) proteins and also fusions to flo galactosidase containing differing amounts of the amino terminus of the VP1/2 polypeptide. Although each of these was expressed at high levels and the majority were produced as full-length proteins, only one was soluble. This soluble polypeptide, p132, is a/3-galactosidase fusion protein that includes 145 amino acids from B19 which are entirely derived from the region unique to VP1. Despite containing such a small portion of VP1, which itself constitutes only 4% of total capsid protein, p132 reacted with all our known anti-B19 IgM-positive human serum samples. We conclude that this region contains epitopes which must be prominently exposed on the intact virus. We have demonstrated the use of this recombinant antigen in a simple diagnostic assay for B19-specific antibodies which can be used for initial screening of human serum samples. In a survey of 103 serum specimens, our ELISA positively identified all samples (19/19) which were positive by IgM antibody capture radioimmunoassay. The recombinant p132 antigen is efficiently produced and readily purified from E. coli, and its use as a diagnostic antigen should increase the availability of routine clinical testing for human parvovirus infection.

show abstract

Prospective study of human parvovirus (B19) infection in pregnancy

Cited by 54 publications

References 0 publications

Human Parvovirus B19: Molecular Virology, Clinical Features, Prevalence, Diagnosis and Control

Human Parvovirus B19: Molecular Virology, Clinical Features, Prevalence, Diagnosis and Control

Comparison of Three Commercially Available Serologic Assays Used To Detect Human Parvovirus B19-Specific Immunoglobulin M (IgM) and IgG Antibodies in Sera of Pregnant Women

The production of human parvovirus capsid proteins in Escherichia coli and their potential as diagnostic antigens

Contact Info

Product

Resources

About